dc.creator | Marchesi, Francesco | es |
dc.creator | Salmanton-García, Jon | es |
dc.creator | Emarah, Ziad | es |
dc.creator | Piukovics, Klára | es |
dc.creator | Nucci, Marcio | es |
dc.creator | López-García, Alberto | es |
dc.creator | Espigado Tocino, Ildefonso | es |
dc.creator | Pagano, Livio | es |
dc.date.accessioned | 2024-01-31T14:53:32Z | |
dc.date.available | 2024-01-31T14:53:32Z | |
dc.date.issued | 2023-01 | |
dc.identifier.citation | Marchesi, F., Salmanton-García, J., Emarah, Z., Piukovics, K., Nucci, M., López-García, A.,...,Pagano, L. (2023). COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica, 108 (1), 22-33. https://doi.org/10.3324/haematol.2022.280847. | |
dc.identifier.issn | 0390-6078 | es |
dc.identifier.uri | https://hdl.handle.net/11441/154360 | |
dc.description.abstract | Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The
optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult
AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had
received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The
chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106.
After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML
(26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age,
and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine
patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed
(80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was
significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021
and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a
high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML
treatment, whenever possible. | es |
dc.format | application/pdf | es |
dc.format.extent | 12 p. | es |
dc.language.iso | eng | es |
dc.publisher | Ferrata Storti Foundation | es |
dc.relation.ispartof | Haematologica, 108 (1), 22-33. | |
dc.rights | Atribución-NoComercial 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.title | COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Instituto de Biomedicina de Sevilla (IBIS) | |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | |
dc.relation.publisherversion | https://haematologica.org/article/view/haematol.2022.280847 | es |
dc.identifier.doi | 10.3324/haematol.2022.280847 | es |
dc.journaltitle | Haematologica | es |
dc.publication.volumen | 108 | es |
dc.publication.issue | 1 | es |
dc.publication.initialPage | 22 | es |
dc.publication.endPage | 33 | es |